| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | PHA-665752 | CCLE | pan-cancer | AAC | -0.092 | 0.05 |
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.067 | 0.05 |
| mRNA | SCH-79797 | CTRPv2 | pan-cancer | AAC | 0.072 | 0.05 |
| mRNA | alvocidib | CTRPv2 | pan-cancer | AAC | 0.1 | 0.05 |
| mRNA | GSK4112 | CTRPv2 | pan-cancer | AAC | -0.075 | 0.05 |
| mRNA | GW843682X | CTRPv2 | pan-cancer | AAC | 0.069 | 0.05 |
| mRNA | Bortezomib | GDSC1000 | pan-cancer | AAC | -0.098 | 0.06 |
| mRNA | AZD6482 | GDSC1000 | pan-cancer | AAC | -0.063 | 0.06 |
| mRNA | Epothilone B | GDSC1000 | pan-cancer | AAC | 0.068 | 0.06 |
| mRNA | BRD-K17060750 | CTRPv2 | pan-cancer | AAC | -0.072 | 0.06 |